Genomics Archives

Predictimmune

We are delighted to announce that the University of Cambridge Enterprise Fund IV and the Parkwalk Opportunities Fund have closed an investment in Predictimmune Limited, a spinout company from the University of Cambridge. Predictimmune is developing prognostic tests… Read More

Congenica

We are delighted to announce that the Parkwalk Opportunities Fund and the Parkwalk Technology Fund VII have invested in Congenica Limited, which spun out of the Wellcome Trust Sanger Institute and Department of Health. Congenica has developed software… Read More

Quethera

Quethera, a spin-out from the University of Cambridge, is a gene therapy company developing a novel treatment for glaucoma. The company aims to deliver gene products for neuroprotectants and their receptors directly to the eye, which will provide long term… Read More

PhoreMost

PhoreMost has developed a next-generation phenotypic screening platform called ‘Site-Seeker’ to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for… Read More

Horizon Discovery

Horizon’s basic science and translational research knowledge deployed in combination with best-in-class translational genomics platforms, products and services provides meaningful solutions to the challenges of translational researchers.

DefiniGEN

DefiniGEN provides human cells to the drug discovery sector for use in lead optimization and toxicity programmes.